4.5 Article

Enhanced interaction between Hsp90 and raptor regulates mTOR signaling upon T cell activation

期刊

MOLECULAR IMMUNOLOGY
卷 46, 期 13, 页码 2694-2698

出版社

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.molimm.2009.05.185

关键词

mTOR; Raptor; Hsp90; T cell; Anergy; Rapamycin

资金

  1. NIH [R01CA098109, R01CA14227]

向作者/读者索取更多资源

The mammalian target of rapamycin (mTOR) is an evolutionarily conserved kinase which plays a role in integrating environmental cues. mTOR signals via two complexes: TORC1, which contains the Regulatory Associated Protein of TOR (raptor), and TORC2, which contains the Rapamycin-insensitive Companion of TOR (rictor). The immunosuppressive/anti-cancer agent rapamycin inhibits TORC1 function by disrupting the mTOR-raptor interaction. In an effort to understand the downstream consequences of TORC1 activation in T cells we performed a proteomic analysis of raptor binding proteins. Using this approach we have identified Hsp90 as an activation-induced binding partner of raptor in T cells. Pharmacologic inhibition of Hsp90 leads to a decrease in raptor expression and TORC1 activity. Furthermore, full T cell activation during Hsp90 blockade leads to T cell tolerance in the form of anergy. Overall, our findings suggest that Hsp90 inhibitors might represent a novel means of promoting T cell tolerance. (C) 2009 Elsevier Ltd. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Review Medicine, Research & Experimental

Hypoxia Reduction Sensitizes Refractory Cancers to Immunotherapy

Priyamvada Jayaprakash, Paolo Dario Angelo Vignali, Greg M. Delgoffe, Michael A. Curran

Summary: To support their growth, cancers need to increase their blood vessel density for oxygen and nutrient delivery. However, this irregular vasculature results in insufficient oxygen supply, leading to tumor hypoxia. In hypoxic and nutrient-deprived conditions, tumors and suppressive stroma thrive while antitumor immunity weakens. Reversing cancer hypoxia has the potential to improve the survival and function of tumor-infiltrating T cells and make tumors responsive to immunotherapy.

ANNUAL REVIEW OF MEDICINE (2022)

Article Microbiology

Fungal sensing enhances neutrophil metabolic fitness by regulating antifungal Glut1 activity

De-Dong Li, Chetan V. Jawale, Chunsheng Zhou, Li Lin, Giraldina J. Trevejo-Nunez, Syed A. Rahman, Steven J. Mullet, Jishnu Das, Stacy G. Wendell, Greg M. Delgoffe, Michail S. Lionakis, Sarah L. Gaffen, Partha S. Biswas

Summary: This study reveals the mechanism of metabolic remodeling in neutrophils during the immune response against fungal pathogens. Neutrophils upregulate glucose uptake by selectively expressing glucose transporter 1 (Glut1), which enhances their immune response against Candida albicans infection. The host-pathogen interaction also increases glycolytic activity in neutrophils through regulating Glut1 expression, localization, and function.

CELL HOST & MICROBE (2022)

Article Immunology

Tumor microenvironmental signals reshape chromatin landscapes to limit the functional potential of exhausted T cells

B. Rhodes Ford, Paolo D. A. Vignali, Natalie L. Rittenhouse, Nicole E. Scharping, Ronal Peralta, Konstantinos Lontos, Andrew T. Frisch, Greg M. Delgoffe, Amanda C. Poholek

Summary: The response rates to immunotherapy in solid tumors remain low due to the prevalence of terminally exhausted T cells. This study used CUT&RUN method to analyze the histone modification landscape of tumor-infiltrating CD8(+) T cells and found unexpected chromatin features in terminally exhausted T cells that limit their transcriptional potential. The study also linked increased histone bivalency to hypoxia exposure and showed that hypoxia-insensitive histone demethylase Kdm6b can increase cell function and promote antitumor immunity.

SCIENCE IMMUNOLOGY (2022)

Article Oncology

Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma

Andrew W. Hahn, Ashley Menk, Dayana B. Rivadeneira, Ryan C. Augustin, Mingchu Xu, Jun Li, Xiaogang Wu, Aditya K. Mishra, Tuba N. Gide, Camelia Quek, Yan Zang, Christine N. Spencer, Alexander M. Menzies, Carrie R. Daniel, Courtney W. Hudgens, Theodore Nowicki, Lauren E. Haydu, M. A. Wadud Khan, Vancheswaran Gopalakrishnan, Elizabeth M. Burton, Jared Malke, Julie M. Simon, Chantale Bernatchez, Nagireddy Putluri, Scott E. Woodman, Y. N. Vashisht Gopal, Renato Guerrieri, Grant M. Fischer, Jian Wang, Khalida M. Wani, John F. Thompson, Jeffrey E. Lee, Patrick Hwu, Nadim Ajami, Jeffrey E. Gershenwald, Georgina Long, Richard A. Scolyer, Michael T. Tetzlaff, Alexander J. Lazar, Dirk Schadendorf, Jennifer A. Wargo, John M. Kirkwood, Ralph J. DeBerardinis, Han Liang, Andrew Futreal, Jianhua Zhang, James S. Wilmott, Weiyi Peng, Michael A. Davies, Greg M. Delgoffe, Yana G. Najjar, Jennifer L. McQuade

Summary: This study investigated the association between body mass index (BMI) and tumor or microbiome characteristics in patients with metastatic melanoma. The findings suggest that the host metabolic phenotype influences melanoma metabolism and may explain the improved outcomes observed in overweight/obese patients treated with immune checkpoint inhibitors and targeted therapies.

CLINICAL CANCER RESEARCH (2023)

Article Cell Biology

Thymidine rescues ATR kinase inhibitor-induced deoxyuridine contamination in genomic DNA, cell death, and interferon-a/f3 expression

Norie Sugitani, Frank P. Vendetti, Andrew J. Cipriano, Pinakin Pandya, Joshua J. Deppas, Tatiana N. Moiseeva, Sandra Schamus-Haynes, Yiyang Wang, Drake Palmer, Hatice U. Osmanbeyoglu, Anna Bostwick, Nathaniel W. Snyder, Yi-Nan Gong, Katherine M. Arid, Greg M. Delgoffe, Jan H. Beumer, Christopher J. Bakkenist

Summary: ATR kinase plays an important role in the DNA damage response and cell cycle checkpoints. ATR kinase inhibitors (ATRi's) have shown to enhance CD8+ T cell-dependent anti-tumor responses in mice. In this study, it is found that ATRi's induce CDK1-dependent origin firing and decrease nucleotide biosynthesis in activated CD8+ T cells. These effects result in dU contamination, R loops, RNA-DNA polymerase collisions, and interferon-alpha/beta (IFN-alpha/beta). Thymidine partially rescues ATRi-induced dU contamination and cell death in proliferating CD8+ T cells, as well as ATRi-induced cancer cell death. It is suggested that ATRi-induced dU contamination contributes to leukocytopenia and inflammation, and is important for CD8+ T cell-dependent anti-tumor responses.

CELL REPORTS (2022)

Article Immunology

Hypoxia drives CD39-dependent suppressor function in exhausted T cells to limit antitumor immunity

Paolo D. A. Vignali, Kristin DePeaux, McLane J. J. Watson, Chenxian Ye, B. Rhodes Ford, Konstantinos Lontos, Nicole K. K. McGaa, Nicole E. E. Scharping, Ashley V. V. Menk, Simon C. C. Robson, Amanda C. C. Poholek, Dayana B. B. Rivadeneira, Greg M. M. Delgoffe

Summary: CD8(+) T cells play a crucial role in cancer cell elimination. Exhaustion, a hypofunctional state, can be induced in these cells by factors in the tumor microenvironment (TME). Highly exhausted T (tT(ex)) cells, resistant to checkpoint blockade immunotherapy, resemble CD4(+)Foxp3(+) regulatory T cells and suppress T cell proliferation through CD39-generated immunosuppressive adenosine. Restricting CD39 in endogenous CD8(+) T cells slows tumor progression, improves immunotherapy response, and enhances infiltration of tumor-specific T cells. Induced by tumor hypoxia, CD39 expression on tT(ex) cells can be mitigated to reduce their suppressive effects. Hence, targeting or eliminating tT(ex) cells in the TME could enhance immunotherapy efficacy.

NATURE IMMUNOLOGY (2023)

Article Oncology

The effect of opioids on the efficacy of immunotherapy in recurrent/ metastatic squamous cell carcinoma of the head and neck

Nicole N. Scheff, Marci L. Nilsen, Jinhong Li, Alexandria L. Harris, Rajesh Acharya, Andrew Swartz, Ronan W. Hsieh, Jennifer L. Anderson, Robert L. Ferris, Ashley V. Menk, Greg M. Delgoffe, Dan P. Zandberg

Summary: This study evaluated the impact of opioids on the efficacy of immunotherapy in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) patients. The results showed that higher opioid dosages were associated with lower progression-free survival and overall survival, as well as lower CD8+ T cell counts in the tumor microenvironment.

ORAL ONCOLOGY (2023)

Article Oncology

Mesothelin-targeting T cells bearing a novel T cell receptor fusion construct (TRuC) exhibit potent antitumor efficacy against solid tumors

Jian Ding, Sarah Guyette, Brett Schrand, Jessica Geirut, Holly Horton, Guangwu Guo, Greg Delgoffe, Ashley Menk, Patrick A. Baeuerle, Robert Hofmeister, Robert Tighe

Summary: TRuC-T cells utilize all signaling subunits of the TCR to activate T cells and effectively kill MSLN+ tumor cells, showing comparable efficacy to MSLN-targeted CAR-T cells. However, TRuC-T cells exhibit faster tumor rejection kinetics, earlier intratumoral accumulation, and signs of activation. Metabolic profiling also indicates that TRuC-T cells have lower glycolytic activity and higher mitochondrial metabolism than CAR-T cells. These findings highlight TRuC-T cells as a promising cell therapy for MSLN-expressing cancers.

ONCOIMMUNOLOGY (2023)

Article Oncology

Metabolic reprogramming via an engineered PGC-1α improves human chimeric antigen receptor T-cell therapy against solid tumors

Konstantinos Lontos, Yiyang Wang, Supriya K. Joshi, Andrew T. Frisch, McLane J. Watson, Alok Kumar, Ashley Menk, Yupeng Wang, Rachel Cumberland, Jason Lohmueller, Esteban Carrizosa, Benjamin Boyerinas, Greg M. Delgoffe

Summary: This study demonstrates that an engineered version of the inhibitory transcription factor PGC-1 alpha can metabolically reprogram human CAR-T cells, resulting in improved in vivo efficacy for the treatment of solid tumors. In contrast, a truncated version of PGC-1 alpha, NT-PGC-1 alpha, did not improve the in vivo outcomes.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2023)

Article Oncology

Metformin is associated with improved clinical outcomes in patients with melanoma: a retrospective, multi-institutional study

Ryan C. Augustin, Ziyu Huang, Fei Ding, Shuyan Zhai, Jennifer McArdle, Anthony Santisi, Michael Davis, Cindy Sander, Diwakar Davar, John M. Kirkwood, Greg M. Delgoffe, Allison Betof Warner, Yana G. Najjar

Summary: In this study, it was found that metformin treatment in diabetic melanoma patients is associated with lower recurrence rates, higher survival rates, and reduced incidence of brain metastases.

FRONTIERS IN ONCOLOGY (2023)

Article Medicine, Research & Experimental

The schedule of ATR inhibitor AZD6738 can potentiate or abolish antitumor immune responses to radiotherapy

Frank P. Vendetti, Pinakin Pandya, David A. Clump, Sandra Schamus-Haynes, Meysam Tavakoli, Maria diMayorca, Naveed M. Islam, Jina Chang, Greg M. Delgoffe, Jan H. Beumer, Christopher J. Bakkenist

Summary: Inhibitors of the ATR kinase can enhance the killing of tumor cells by DNA replication fork-targeting chemotherapies but also affect rapidly proliferating immune cells. Combining ATR inhibitor and radiotherapy can stimulate CD8+ T cell-dependent antitumor responses. The optimal schedule of ATR inhibitor and radiotherapy is determined by the duration of ATR inhibitor treatment, which affects the expansion of tumor antigen-specific CD8+ T cells.

JCI INSIGHT (2023)

Article Immunology

An oncolytic virus-delivered TGFβ inhibitor overcomes the immunosuppressive tumor microenvironment

Kristin Depeaux, Dayana B. Rivadeneira, Konstantinos Lontos, Victoria G. Dean, William G. Gunn, McLane J. Watson, Tianhong Yao, Drew Wilfahrt, Cynthia Hinck, Lukasz Wieteska, Stephen H. Thorne, Andrew P. Hinck, Greg M. Delgoffe

Summary: Oncolytic viruses can induce tumor lysis and activate the tumor microenvironment, but they do not relieve immunosuppressive signals. Engineering oncolytic vaccinia virus to express a potent TGF beta R inhibitor can neutralize TGF beta locally, increase fragility of Treg cells, and achieve a superior therapeutic response.

JOURNAL OF EXPERIMENTAL MEDICINE (2023)

Article Gastroenterology & Hepatology

Excess Dietary Sugar Alters Colonocyte Metabolism and Impairs the Proliferative Response to Damage

Ansen H. P. Burr, Junyi Ji, Kadir Ozler, Heather L. Mentrup, Onur Eskiocak, Brian Yueh, Rachel Cumberland, Ashley V. Menk, Natalie Rittenhouse, Chris W. Marshall, Pailin Chiaranunt, Xiaoyi Zhang, Lauren Mullinax, Abigail Overacre-Delgoffe, Vaughn S. Cooper, Amanda C. Poholek, Greg M. Delgoffe, Kevin P. Mollen, Semir Beyaz, Timothy W. Hand

Summary: This study revealed the direct impact of high-sugar diet on the function of colonic stem cells and transit-amplifying cells using 3-dimensional colonoids and a mouse model of colon damage and repair. The findings showed that high-sugar conditions restrict colonoid development, reduce the expression of proliferative genes, ATP levels, and lead to pyruvate accumulation. Treatment with dichloroacetate restored colonoid growth. Moreover, a high-sugar diet combined with dextran sodium sulfate treatment resulted in severe irreparable colon damage. ISC gene expression was reduced, proliferative potential was impeded, and glycolytic potential was increased without a corresponding increase in aerobic respiration.

CELLULAR AND MOLECULAR GASTROENTEROLOGY AND HEPATOLOGY (2023)

Article Microbiology

Interferon signaling drives epithelial metabolic reprogramming to promote secondary bacterial infection

Grace P. Carreno-Florez, Brian R. Kocak, Matthew R. Hendricks, Jeffrey A. Melvin, Katrina B. Mar, Jessica Kosanovich, Rachel L. Cumberland, Greg M. Delgoffe, Sruti Shiva, Kerry M. Empey, John W. Schoggins, Jennifer M. Bomberger

Summary: Viral infections can make the host susceptible to secondary bacterial infections, and this study identified specific interferon-stimulated genes (ISGs) that promote Pseudomonas aeruginosa infection. The mechanism of action was also investigated, revealing the role of hexokinase 2 (HK2) in mediating metabolic changes and lactate secretion to enhance bacterial infection. These findings improve our understanding of how the host immune response can lead to viral-bacterial co-infection.

PLOS PATHOGENS (2023)

Review Medicine, Research & Experimental

Fighting in a wasteland: deleterious metabolites and antitumor immunity

McLane J. Watson, Greg M. Delgoffe

Summary: The tumor microenvironment depletes essential nutrients and produces toxic metabolites that shape immune cell function and impact cancer immunotherapy.

JOURNAL OF CLINICAL INVESTIGATION (2022)

暂无数据